Quince Regains Nasdaq Bid-Price Compliance; $50M MVLS Deficiency Remains
Summary
Quince Therapeutics has regained compliance with Nasdaq's $1.00 minimum bid price requirement, having maintained the price for 10 consecutive business days. This positive development addresses one of the company's ongoing Nasdaq listing deficiencies, which were previously highlighted in recent SEC filings (PRE 14A, DEF 14A) proposing a reverse stock split. However, the company explicitly stated it remains non-compliant with the $50 million Market Value of Listed Securities (MVLS) requirement. For a company with a market capitalization of approximately $20 million, this MVLS deficiency represents a significant hurdle. The company has until September 14, 2026, to regain MVLS compliance, and the outcome of the proposed reverse stock split could influence this.
At the time of this announcement, QNCX was trading at $1.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20M. The 52-week trading range was $0.80 to $45.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.